Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome

被引:40
|
作者
Mei, Lijun [1 ]
Zhou, Jiaoli [2 ]
Su, Yimo [2 ]
Mao, Kunhong [2 ]
Wu, Jing [2 ]
Zhu, Caicai [2 ]
He, Ling [1 ,2 ]
Cui, Ying [3 ]
机构
[1] Jiangxi Univ Tradit Chinese Med, Affiliated Hosp, Nanchang 330006, Jiangxi, Peoples R China
[2] Jiangxi Univ Tradit Chinese Med, Nanchang 330004, Jiangxi, Peoples R China
[3] Jiangxi Maternal & Child Hlth Hosp, Nanchang 330006, Jiangxi, Peoples R China
关键词
Diarrhea-predominant irritable bowel syndrome; Gut microbiota; Functional prediction; INTESTINAL MICROBIOTA; FECAL MICROBIOTA; PATHOGENESIS; DYSBIOSIS;
D O I
10.1186/s12876-021-01693-w
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Irritable bowel syndrome (IBS) is common and difficult to treat and its pathogenesis is closely related to gut microbiota. However, differences in gut microbiota of patients in different regions make it more difficult to elucidate the mechanism of IBS. We performed an analysis of gut microbiota composition and functional prediction in Chinese patients with diarrhea-predominant IBS (IBS-D). Methods: Fecal samples were obtained from 30 IBS-D patients and 30 healthy controls (HCs) in Nanchang, China. Using 16S gene sequence profiles, we analyzed the abundance of dominant microbiota at different taxonomy levels. Based on 16S information, Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) was used to predicting the function of gut microbiota. Results: Compared to HCs, gut microbiota richness but not diversity was decreased in IBS-D patients. The abundant phyla Firmicutes, Fusobacteria and Actinobacteria decreased significantly, and Proteobacteria increased significantly in IBS-D patients. PICRUSt indicated that function expression of gut microbiota in IBS-D patients was up-regulated in metabolism of cofactors and vitamins, xenobiotics biodegradation and metabolism, and down-regulated in environmental adaptation, cell growth and death. Conclusions: Compared with the normal population in China, IBS-D patients are characterized by complex and unstable gut microbiota, which may influence inflammation and metabolism of the host.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] The function of the gut microbiota-bile acid-TGR5 axis in diarrhea-predominant irritable bowel syndrome
    Zhan, Kai
    Wu, Haomeng
    Xu, Yongyin
    Rao, Kehan
    Zheng, Huan
    Qin, Shumin
    Yang, Yuanming
    Jia, Rui
    Chen, Weihuan
    Huang, Shaogang
    [J]. MSYSTEMS, 2024, 9 (03)
  • [32] Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome
    Wang Zhe
    Xu Cong-Min
    Liu Yi-Xuan
    Wang Xiao-Qi
    Zhang Lu
    Li Mo
    Zhu Shi-Wei
    Xie Zhong-Jie
    Wang Pei-Hong
    Duan Li-Ping
    Zhu Huai-Qiu
    [J]. 中华医学杂志(英文版), 2019, 132 (08) : 889 - 904
  • [33] The Fecal Microbiome in Children With Diarrhea-Predominant Irritable Bowel Syndrome
    Michail, Sonia
    Kenche, Harshavadran
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S14 - S14
  • [34] Rifaximin in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome
    Dai, Cong
    Jiang, Min
    Sun, Ming-Jun
    [J]. GASTROENTEROLOGY, 2017, 152 (06) : 1629 - +
  • [35] Diagnostic Yield of Testing in Diarrhea-predominant Irritable Bowel Syndrome
    Manolakis, Catherine
    Di Palma, Jack
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S490 - S490
  • [36] Advancements in drug development for diarrhea-predominant irritable bowel syndrome
    Dothel, Giovanni
    Barbaro, Maria Raffaella
    Raschi, Emanuel
    Barbara, Giovanni
    De Ponti, Fabrizio
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (03) : 251 - 263
  • [37] Targeting diarrhea-predominant irritable bowel syndrome: hopes or hypes?
    Bassotti, Gabrio
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024,
  • [38] Decreased mucosal cytokines in diarrhea-predominant irritable bowel syndrome
    Chang, L
    Anton, P
    Elliott, J
    Reinholdt, J
    Taing, P
    Mayer, E
    [J]. GASTROENTEROLOGY, 2002, 122 (04) : A552 - A552
  • [39] RIFAXIMIN IS A SAFE THERAPY FOR DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME
    Weinstock, Leonard B.
    Pimentel, Mark
    Heimanson, Zeev
    Lembo, Anthony
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2018, 33 : S331 - S332
  • [40] Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome
    Carroll, Ian M.
    Chang, Young-Hyo
    Park, Jiwon
    Sartor, R. Balfour
    Ringel, Yehuda
    [J]. GUT PATHOGENS, 2010, 2